Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Efficacy and Safety of Electroacupuncture in the Treatment of Esophageal Symptoms in Non-erosive Reflux Disease (NERD) Patients

10 november 2026 uppdaterad av: Linda Zhong, Nanyang Technological University

Investigating the Efficacy and Safety of Electroacupuncture in the Treatment of Esophageal Symptoms in Non-erosive Reflux Disease (NERD) Patients: A Pilot, Randomized Double-blinded, Sham-controlled Trial

The goal of this clinical trial is to learn if acupuncture works to treat non-erosive reflux disease (NERD) patients. The main questions it aims to answer are:

  1. Electroacupuncture (EA) is superior to sham EA in terms of easing the symptom severity of NERD.
  2. Acupuncture is able to influence gastrointestinal function, autonomic regulation, and stress responses in NERD patients.

Participants will:

  1. Receive acupuncture treatment twice per week for 6 weeks.
  2. Leave plasma, serum, saliva, stool, and urine samples at baseline, mid-treatment, and end-of-treatment.
  3. Complete patient-reported-outcomes (PROs) at baseline, mid-treatment, and end-of-treatment

Studieöversikt

Status

Har inte rekryterat ännu

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Beräknad)

96

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

      • Singapore, Singapore, S637551
        • Nanyang Technological University, School of Biological Sciences
        • Kontakt:
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

21 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Adults aged 21 to 75 years at the time of consent;
  • Presence of heartburn, regurgitation or chest pain before screening with a frequency of at least twice a week;
  • No evidence of esophageal mucosal injury on endoscopy within the past 5 years;
  • GERD-Q score ≥8 (indicating active GERD symptoms);
  • Ability and willingness to provide written informed consent to participate.

Exclusion Criteria:

  • Structural or organic gastrointestinal disease, including but not limited to:

    1. gastrointestinal malignancy,
    2. eosinophilic esophagitis,
    3. esophageal stricture, varices, or infections,
    4. active peptic ulcer disease,
    5. gastric or duodenal tumors;
  • Presence of alarming symptoms (e.g. severe dysphagia, hematemesis, unexplained weight loss, or hematochezia, etc.);

  • History of digestive tract surgery or esophageal interventions, including chemotherapy, radiotherapy, radiofrequency ablation, endoscopic mucosal resection, or cryotherapy;

  • Use of prohibited medical treatment:

    1. acupuncture treatment on the abdomen and chest within past 1 month,
    2. concomitant medication affecting gastrointestinal motility or visceral sensitivity (antidiarrheals, antidepressants, narcotic analgesics, anticholinergics, etc.),
    3. antibiotics, prebiotics, probiotics, or immunosuppressants within 1 month prior to screening;
  • Presence of an implanted cardiac pacemaker;

  • History of hypersensitivity to acupuncture, or needle phobia;

  • Severe psychiatric illness (e.g. schizophrenia, major depression, dementia), cognitive impairment, or other conditions likely to compromise adherence to study procedures;

  • Pregnant or breastfeeding;

  • Current participation in other clinical trials that could interfere with study outcomes.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Electroacupuncture (EA)

The WHO Standardized Acupuncture Points Location will be used to identify the location of these acupoints: ST36 Zusanli, PC6 Neiguan, CV12 Zhongwan, LR3 Taichong, SP4 Gongsun; and auxiliary acupoints added according to symptom severity: PC7 Daling, ST44 Neiting, EX-HN3 Yintang, ST37 Shangjuxu, SP6 Sanyinjiao, LU7 Lieque. After sterilizing the skin, needles of 0.25 mm in diameter and 25-40 mm in length will be inserted into the acupoints to a depth of 10-30 mm outward and upward slightly. Needles will be lifted, thrust, and twirled evenly 3 times to achieve "de-qi". Paired electrodes of the EA apparatus will be attached transversely to the acupoint respectively with a continuous wave of 2/100 Hz and a current intensity of 1-5 mA (preferably with the skin around the acupoints shivering mildly without pain) for 30 min.

The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.

Sham Comparator: Sham-electroacupuncture (SEA)

The sham electroacupuncture group (SEA) penetrates acupuncture on non-acupuncture points (1 B-cun away from the acupuncture point and meridian). The same type of acupuncture needles will be used for SEA with the exact skin sterilization method. Insertion depth will be approximately less than 10 mm. The electrostimulator will not be switched on for these patients. All needles will be removed after 30 min of needle retention.

The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Gastroesophageal Reflux Disease Questionnaire (GERDQ)
Tidsram: From enrollment to the end of follow-up at 16 weeks

≥ 50% reduction in total GERD-Q score or normalization (<8)

From enrollment to the end of follow-up at 16 weeks
Gastrointestinal Symptom Rating scale (GSRS)
Tidsram: From enrollment to the end of follow-up at 16 weeks

≥ 0.5 point decrease in mean GSRS Reflux domain value

From enrollment to the end of follow-up at 16 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD)
Tidsram: From enrollment to the end of follow-up at 16 weeks

≥ 0.5 point improvement on the mean QOLRAD score

From enrollment to the end of follow-up at 16 weeks
Euro QoL (EQ-5D-5L)
Tidsram: From enrollment to the end of follow-up at 16 weeks

change in index utility

From enrollment to the end of follow-up at 16 weeks
Hospital Anxiety and Depression Scale (HADS)
Tidsram: From enrollment to the end of follow-up at 16 weeks

categorical shift from ≥ 11 to < 11 or ≥ 8 to < 8, or ≥ 1.5 point reduction per HADS-A and HADS-D subscale

From enrollment to the end of follow-up at 16 weeks
Visceral Sensitivity Index (VSI)
Tidsram: From enrollment to the end of follow-up at 16 weeks

≥ 15% reduction from baseline

From enrollment to the end of follow-up at 16 weeks
Esophageal Hypervigilance and Anxiety Scale (EHAS) Short Form
Tidsram: From enrollment to the end of follow-up at 16 weeks

≥ 15% reduction from baseline

From enrollment to the end of follow-up at 16 weeks
Simplified Constitution of Chinese Medicine Questionnaire (CCMQ)
Tidsram: At baseline
At baseline
Traditional Chinese medicine functional gastrointestinal disorders syndrome scale (TCM-FGID)
Tidsram: From enrollment to the end of follow-up at 16 weeks

(Total syndrome score before treatment - Total syndrome score after treatment) / Total syndrome score before treatment × 100%

From enrollment to the end of follow-up at 16 weeks
Bang's blinding index (BBI)
Tidsram: End of first week and sixth week of intervention
End of first week and sixth week of intervention
James' blinding index (JBI)
Tidsram: End of first week and sixth week of intervention
End of first week and sixth week of intervention
Patient's global impression of change (PGIC)
Tidsram: From mid-treatment to the end of follow-up at 16 week
From mid-treatment to the end of follow-up at 16 week
Daily patient diary
Tidsram: From enrollment to the end of follow-up at 16 weeks
From enrollment to the end of follow-up at 16 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Linda LD Zhong, PhD, Nanyang Technological University

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 november 2026

Primärt slutförande (Beräknad)

1 december 2027

Avslutad studie (Beräknad)

1 mars 2028

Studieregistreringsdatum

Först inskickad

10 november 2026

Först inskickad som uppfyllde QC-kriterierna

10 november 2026

Första postat (Faktisk)

16 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

IPD sharing will be available upon request.

Tidsram för IPD-delning

Data will become available within 7 years after completion of the clinical trial.

Kriterier för IPD Sharing Access

Individual participant data (IPD) will be made available to qualified researchers upon request. To access the data, researchers must submit a formal request, which will be reviewed and approved by the data-sharing committee. Data access will be granted for research purposes only and will require adherence to data use agreements and ethics guidelines.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • ICF
  • ANALYTIC_CODE
  • CSR

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera